drugset
drugset / Trial / NCT00004180

Rosiglitazone in Treating Patients With Liposarcoma

NCT00004180 ↗

Phase 2 Completed 32 enrolled Dana-Farber Cancer Institute National Cancer Institute (NCI) · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

RATIONALE: Rosiglitazone may help liposarcoma cells develop into normal fat cells. PURPOSE: Phase II trial to study the effectiveness of rosiglitazone in treating patients who have liposarcoma.

Timeline

Start
1999-10
Primary completion
2006-03
Completion
2015-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Rosiglitazone Small molecule 4 mg Oral

Indications

sarcoma